A review of human phase 0 (microdosing) clinical trials following the US food and drug administration exploratory investigational new drug studies guidance

Lappin, Graham and Garner, R. Colin (2006) A review of human phase 0 (microdosing) clinical trials following the US food and drug administration exploratory investigational new drug studies guidance. International Journal of Pharmaceutical Medicine, 20 (3). pp. 159-165. ISSN 1364-9027

Full content URL: http://link.springer.com/article/10.2165%2F0012436...

Full text not available from this repository.

Item Type:Article
Item Status:Live Archive


Microdosing, or human phase 0 clinical trials, is a technique whereby subpharmacological doses of prospective drug candidates are administered to human volunteers. A microdose study provides early pharmacokinetic data in humans and only requires minimal preclinical toxicology safety testing. A microdose is defined as 100th of the pharmacological dose (or predicted pharmacological dose) or a maximum of 100μg. Microdosing is a relatively recent innovation and there remains a degree of uncertainty as to whether such a small dose will adequately predict the pharmacokinetics of the therapeutically active dose. Notwithstanding this, in situations when traditional methods such as in vitro and laboratory animal models prove to be unreliable, microdosing can offer the supporting and alternative data on which to select suitable drug candidates for development, prior to commencing expensive full phase I clinical trials. The current published data on microdosing is somewhat sparse, although there have been a few papers in recent times. This paper is the first compressive review of the microdosing concept since the publication of the US Food and Drug Administration exploratory IND study guidance in January 2006, which covers the preclinical requirements to enable a microdose study in humans to take place. © 2006 Adis Data Information BV. All rights reserved.

Additional Information:cited By (since 1996) 7
Keywords:alpha 1 adrenergic receptor blocking agent, antiestrogen, cytochrome P450 3A4, diazepam, erythromycin, fluconazole, glycoprotein P, midazolam, tolbutamide, tubercidin, unclassified drug, warfarin, zk 253, area under the curve, clinical trial, dose calculation, dose time effect relation, drug bioavailability, drug blood level, drug clearance, drug cost, drug distribution, drug half life, drug research, drug safety, food and drug administration, high performance liquid chromatography, human, liquid chromatography, methodology, microdosing, nonhuman, patient participation, priority journal, review, tandem mass spectrometry, toxicology, volunteer
Subjects:B Subjects allied to Medicine > B210 Pharmacology
B Subjects allied to Medicine > B200 Pharmacology, Toxicology and Pharmacy
Divisions:College of Science > School of Pharmacy
Related URLs:
ID Code:8231
Deposited On:27 Mar 2013 16:05

Repository Staff Only: item control page